Xupeng Yang

Xupeng Yang

Auto-generated profile, based on publicly available information

Xupeng Yang

Department of Liver Surgery and Transplantation, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Science
Verified
Journal Article
Closed access
JMJiaqiang Ma
Jiaqiang Ma
YWYing Cheng Wu
Ying Cheng Wu
LMLifeng Ma
Lifeng Ma
XYXupeng Yang
Xupeng Yang
TZTiancheng Zhang
Tiancheng Zhang
QGQiang Gao
Qiang Gao
B lymphocytes are essential mediators of humoral immunity and play multiple roles in human cancer. To decode the functions of tumor-infiltrating B cells, we generated a B cell blueprint encompassing single-cell transcriptome, B cell–receptor repertoire, and chromatin accessibility data across 20 different cancer types (477 samples, 269 patients). B cells harbored extraordinary heterogeneity and comprised 15 subsets, which could be grouped into two independent developmental paths (extrafollicular versus germinal center). Tumor types grouped into the extrafollicular pathway were linked with worse clinical outcomes and resistance to immunotherapy. The dysfunctional extrafollicular program was associated with glutamine-derived metabolites through epigenetic-metabolic cross-talk, which promoted a T cell–driven immunosuppressive program. These data suggest an intratumor B cell balance between extrafollicular and germinal-center responses and suggest that humoral immunity could possibly be harnessed for B cell–targeting immunotherapy.

17 November 2026 in Cancer Discovery
Verified
Journal Article
Closed access
CYChen Yang
Chen Yang
NXNuo Xu
Nuo Xu
SJShuyi Ji
Shuyi Ji
XCXifu Cheng
Xifu Cheng
QLQian Li
Qian Li
CWCun Wang
Cun Wang
Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (∼1 to 2%), yet its occurrence portends lethal disease progression. In this study, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20% to 30% of patients with iCCA can be classified as STP high and experience ASC-like dismal outcomes. Mechanistically, FOS-like 1 (FOSL1) acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral prostaglandin (PG) E2 accumulation drives neutrophil-mediated FOXP3-negative type I regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immunopermissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235). Significance: Latent squamous plasticity defines a common yet histologically occult high-risk state in iCCA, driven by FOSL1-dependent enhancer reprogramming and coupled to a PGE2-dependent neutrophil–Tr1 immunosuppressive circuit. By integrating STP-based stratification with celecoxib repurposing, this study identifies latent squamous plasticity as a clinically actionable vulnerability to improve iCCA treatment responsiveness.